Etravirine

Bettina M. Knoll, Sandro Vento, Zelalem Temesgen

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Etravirine, formerly known as TMC 125, is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent activity against HIV resistant to currently licensed NNRTIs. It is in its final stage of clinical development and has received fast-track status for review by the U.S. Food and Drug Administration (FDA). In randomized placebo-controlled trials in treatment-experienced patients with confirmed NNRTI resistance, it has shown virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are significant drug interaction issues that will need to be taken into consideration with its use.

Original languageEnglish
Pages (from-to)23-33
Number of pages11
JournalDrugs of Today
Volume44
Issue number1
DOIs
Publication statusPublished - Jan 2008
Externally publishedYes

Fingerprint

etravirine
Reverse Transcriptase Inhibitors
United States Food and Drug Administration
Exanthema
Drug Interactions
Cytochrome P-450 Enzyme System
Randomized Controlled Trials
Placebos
HIV
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology (medical)
  • Pharmacology

Cite this

Knoll, B. M., Vento, S., & Temesgen, Z. (2008). Etravirine. Drugs of Today, 44(1), 23-33. https://doi.org/10.1358/dot.2008.44.1.1152213

Etravirine. / Knoll, Bettina M.; Vento, Sandro; Temesgen, Zelalem.

In: Drugs of Today, Vol. 44, No. 1, 01.2008, p. 23-33.

Research output: Contribution to journalReview article

Knoll, BM, Vento, S & Temesgen, Z 2008, 'Etravirine', Drugs of Today, vol. 44, no. 1, pp. 23-33. https://doi.org/10.1358/dot.2008.44.1.1152213
Knoll, Bettina M. ; Vento, Sandro ; Temesgen, Zelalem. / Etravirine. In: Drugs of Today. 2008 ; Vol. 44, No. 1. pp. 23-33.
@article{610b5bac30da4e5c92b58947a4671bf4,
title = "Etravirine",
abstract = "Etravirine, formerly known as TMC 125, is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent activity against HIV resistant to currently licensed NNRTIs. It is in its final stage of clinical development and has received fast-track status for review by the U.S. Food and Drug Administration (FDA). In randomized placebo-controlled trials in treatment-experienced patients with confirmed NNRTI resistance, it has shown virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are significant drug interaction issues that will need to be taken into consideration with its use.",
author = "Knoll, {Bettina M.} and Sandro Vento and Zelalem Temesgen",
year = "2008",
month = "1",
doi = "10.1358/dot.2008.44.1.1152213",
language = "English",
volume = "44",
pages = "23--33",
journal = "Drugs of Today",
issn = "0025-7656",
publisher = "Prous Science",
number = "1",

}

TY - JOUR

T1 - Etravirine

AU - Knoll, Bettina M.

AU - Vento, Sandro

AU - Temesgen, Zelalem

PY - 2008/1

Y1 - 2008/1

N2 - Etravirine, formerly known as TMC 125, is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent activity against HIV resistant to currently licensed NNRTIs. It is in its final stage of clinical development and has received fast-track status for review by the U.S. Food and Drug Administration (FDA). In randomized placebo-controlled trials in treatment-experienced patients with confirmed NNRTI resistance, it has shown virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are significant drug interaction issues that will need to be taken into consideration with its use.

AB - Etravirine, formerly known as TMC 125, is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) with potent activity against HIV resistant to currently licensed NNRTIs. It is in its final stage of clinical development and has received fast-track status for review by the U.S. Food and Drug Administration (FDA). In randomized placebo-controlled trials in treatment-experienced patients with confirmed NNRTI resistance, it has shown virological efficacy superior to the control arms with comparable rates of adverse events with the exception of rash. Because of its effect on the cytochrome P450 system, there are significant drug interaction issues that will need to be taken into consideration with its use.

UR - http://www.scopus.com/inward/record.url?scp=40949146616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949146616&partnerID=8YFLogxK

U2 - 10.1358/dot.2008.44.1.1152213

DO - 10.1358/dot.2008.44.1.1152213

M3 - Review article

C2 - 18301801

AN - SCOPUS:40949146616

VL - 44

SP - 23

EP - 33

JO - Drugs of Today

JF - Drugs of Today

SN - 0025-7656

IS - 1

ER -